Composition, form of production and packaging
The solution for the / m introduction is clear, colorless or slightly yellowish, with the smell of benzyl alcohol.
1 ml
chondroitin sodium sulfate 100 mg
Excipients: benzyl alcohol - 9 mg, sodium metabisulphite - 1 mg, sodium hydroxide - up to pH 6.0-7.5, water d / u - up to 1 ml.
1 ml - ampoules of colorless glass (5) - packings of cellular contour (1) - packs cardboard.
1 ml - ampoules of colorless glass (5) - packings of cellular contour (2) - packs cardboard.
1 ml - glass syringes with a needle (1) - packings of cellular contour (5) - packs cardboard.
1 ml - glass syringes with a needle (2) - packings of cellular contour (5) - packs cardboard.
1 ml - glass syringes without needles (1) - packings of cellular contour (5) complete with 5 needles - packs of cardboard.
1 ml - glass syringes without needles (2) - packs of cellular contour (5) complete with 10 needles - packs of cardboard.
The solution for the / m introduction is clear, colorless or slightly yellowish, with the smell of benzyl alcohol.
1 ml of 1 amp.
chondroitin sodium sulfate 100 mg 200 mg
Excipients: benzyl alcohol - 18 mg, sodium metabisulphite - 2 mg, sodium hydroxide - up to pH 6.0-7.5, water d / u - up to 2 ml.
2 ml - ampoules of colorless glass (5) - packings of cellular contour (1) - packs cardboard.
2 ml - ampoules of colorless glass (5) - packings of cellular contour (2) - packs cardboard.
2 ml - ampoules of colorless glass (5) - packings of cellular contour (5) - packs cardboard.
2 ml - glass syringes with a needle (1) - packings of cellular contour (5) - packs cardboard.
2 ml - glass syringes with a needle (2) - packings of cellular contour (5) - packs cardboard.
2 ml - glass syringes without needles (1) - packs of cellular contour (5) complete with 5 needles - packs of cardboard.
2 ml - glass syringes without needles (2) - packings of cellular contour (5) complete with 10 needles - packs of cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2017.
PHARMACHOLOGIC EFFECT
High-molecular mucopolysaccharide, which affects the metabolic processes in the hyaline cartilage. It reduces degenerative changes in the cartilaginous tissue of the joints, accelerates the processes of its restoration, stimulates the synthesis of proteoglycans.
When treatment with the drug decreases soreness and improves the mobility of the affected joints. In the treatment of degenerative joint changes with the development of secondary synovitis, a positive effect can be observed as early as 2-3 weeks after the start of the drug administration: pain in the joints decreases, the clinical manifestations of the reactive synovitis disappear, and the volume of movements in the affected joints increases. The therapeutic effect persists for a long time after the end of the course of treatment.
PHARMACOKINETICS
After the / m introduction of chondroitin sulfate is quickly distributed. Already 30 minutes after the injection, it is found in the blood in significant concentrations. Cmax chondroitin sulfate in plasma is achieved after 1 hour, then gradually decreases within 2 days.
Chondroitin sulfate accumulates mainly in the cartilaginous tissue of the joints. Synovial membrane is not an obstacle to penetration of the drug into the joint cavity. In the experiments it was shown that 15 minutes after the IM injection of chondroitin sulfate is found in the synovial fluid, then it penetrates into the articular cartilage, where its C max is reached after 48 hours.
INDICATIONS
Degenerative and dystrophic diseases of the joints and spine:
osteoarthrosis of peripheral joints;
- intervertebral osteochondrosis and osteoarthrosis.
To accelerate the formation of bone callus in fractures.
DOSING MODE
The drug is given in / m at 100 mg every other day. With good tolerability, the dose is increased to 200 mg, starting with the 4th injection.
The course of treatment - 25-30 injections. If necessary, after 6 months, a second course of treatment is possible.
For the formation of bone callus, the course of treatment is 3-4 weeks (10-14 injections every other day).
SIDE EFFECT
Allergic reactions: skin itching, erythema, urticaria, dermatitis.
Local reactions: hemorrhages at the injection site.
CONTRAINDICATIONS
- hypersensitivity to the components of the drug;
bleeding and a tendency to bleeding;
- thrombophlebitis;
- childhood;
- Pregnancy (data on the safety of the drug are not available at the moment);
- lactation period (there are no data on the safety of the drug at present).
PREGNANCY AND LACTATION
Contraindicated in pregnancy and lactation (safety data are not available at this time).
APPLICATION FOR CHILDREN
Contraindicated in childhood use.
SPECIAL INSTRUCTIONS
Use in Pediatrics
Data on the efficacy and safety of chondroitin sulfate in children are currently not available.
Impact on the ability to drive vehicles and manage mechanisms
Information about caution regarding the use of the drug by drivers of vehicles and persons working with potentially dangerous mechanisms is not available.
OVERDOSE
At present, cases of an overdose of chondroitin sulfate have not been reported.
DRUG INTERACTION
It is possible to increase the effect of indirect anticoagulants, antiplatelet agents, fibrinolytic agents, which requires more frequent monitoring of blood clotting values ​​when used simultaneously.
TERMS OF RELEASE FROM PHARMACY
The drug is released by prescription.
TERMS AND CONDITIONS OF STORAGE
The drug should be stored out of reach of children, protected from light at a temperature of no higher than 25 В° C. Shelf life of the solution for IM injection in ampoules is 3 years, in syringes - 2 years.
